These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 26861776)

  • 1. GABA: Inhibition brings new excitement in Parkinson's disease.
    Castela I
    Mov Disord; 2016 Mar; 31(3):297. PubMed ID: 26861776
    [No Abstract]   [Full Text] [Related]  

  • 2. Loss of Striatonigral GABAergic Presynaptic Inhibition Enables Motor Sensitization in Parkinsonian Mice.
    Borgkvist A; Avegno EM; Wong MY; Kheirbek MA; Sonders MS; Hen R; Sulzer D
    Neuron; 2015 Sep; 87(5):976-88. PubMed ID: 26335644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primate models of Parkinson's disease.
    Collier TJ; Steece-Collier K; Kordower JH
    Exp Neurol; 2003 Oct; 183(2):258-62. PubMed ID: 14552866
    [No Abstract]   [Full Text] [Related]  

  • 4. Decreased behavioral response to intranigrally administered GABAA agonist muscimol in the lactacystin model of Parkinson's disease may result from partial lesion of nigral non-dopamine neurons: comparison to the classical neurotoxin 6-OHDA.
    Konieczny J; Czarnecka A; Kamińska K; Lenda T; Nowak P
    Behav Brain Res; 2015 Apr; 283():203-14. PubMed ID: 25655509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymphocytes reduce nigrostriatal deficits in the 6-hydroxydopamine mouse model of Parkinson's disease.
    Ip CW; Beck SK; Volkmann J
    J Neural Transm (Vienna); 2015 Dec; 122(12):1633-43. PubMed ID: 26290125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
    Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
    Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stimulation of delta opioid receptors located in substantia nigra reticulata but not globus pallidus or striatum restores motor activity in 6-hydroxydopamine lesioned rats: new insights into the role of delta receptors in parkinsonism.
    Mabrouk OS; Volta M; Marti M; Morari M
    J Neurochem; 2008 Dec; 107(6):1647-59. PubMed ID: 19094058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Kv7/KCNQ channel blocker XE991 protects nigral dopaminergic neurons in the 6-hydroxydopamine rat model of Parkinson's disease.
    Liu H; Jia L; Chen X; Shi L; Xie J
    Brain Res Bull; 2018 Mar; 137():132-139. PubMed ID: 29174294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential of the cannabinoid CB(2) receptor as a pharmacological target against inflammation in Parkinson's disease.
    Gómez-Gálvez Y; Palomo-Garo C; Fernández-Ruiz J; García C
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Jan; 64():200-8. PubMed ID: 25863279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered melatonin MT
    Kang NH; Carriere CH; Bahna SG; Niles LP
    Brain Res; 2016 Dec; 1652():89-96. PubMed ID: 27693415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small molecule TrkB agonist deoxygedunin protects nigrostriatal dopaminergic neurons from 6-OHDA and MPTP induced neurotoxicity in rodents.
    Nie S; Xu Y; Chen G; Ma K; Han C; Guo Z; Zhang Z; Ye K; Cao X
    Neuropharmacology; 2015 Dec; 99():448-58. PubMed ID: 26282118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic pramipexole treatment induces compulsive behavior in rats with 6-OHDA lesions of the substantia nigra and ventral tegmental area.
    Dardou D; Reyrolle L; Chassain C; Durif F
    Behav Brain Res; 2017 Aug; 332():327-336. PubMed ID: 28634107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopaminergic treatment weakens medium spiny neuron collateral inhibition in the parkinsonian striatum.
    Wei W; Ding S; Zhou FM
    J Neurophysiol; 2017 Mar; 117(3):987-999. PubMed ID: 27927785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IRF2BPL mutation causes nigrostriatal degeneration presenting with dystonia, spasticity and keratoconus.
    Prilop L; Buchert R; Woerz S; Gerloff C; Haack TB; Zittel S
    Parkinsonism Relat Disord; 2020 Oct; 79():141-143. PubMed ID: 32291157
    [No Abstract]   [Full Text] [Related]  

  • 15. Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway.
    Deumens R; Blokland A; Prickaerts J
    Exp Neurol; 2002 Jun; 175(2):303-17. PubMed ID: 12061862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time-course of nigrostriatal neurodegeneration and neuroinflammation in the 6-hydroxydopamine-induced axonal and terminal lesion models of Parkinson's disease in the rat.
    Walsh S; Finn DP; Dowd E
    Neuroscience; 2011 Feb; 175():251-61. PubMed ID: 21145947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of early and delayed treatment with an mGluR5 antagonist on motor impairment, nigrostriatal damage and neuroinflammation in a rodent model of Parkinson's disease.
    Ambrosi G; Armentero MT; Levandis G; Bramanti P; Nappi G; Blandini F
    Brain Res Bull; 2010 Apr; 82(1-2):29-38. PubMed ID: 20100549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcutaneous rotenone rat model of Parkinson's disease: Dose exploration study.
    Zhang ZN; Zhang JS; Xiang J; Yu ZH; Zhang W; Cai M; Li XT; Wu T; Li WW; Cai DF
    Brain Res; 2017 Jan; 1655():104-113. PubMed ID: 27876560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of (-)-sesamin on motor and memory deficits in an MPTP-lesioned mouse model of Parkinson's disease treated with l-DOPA.
    Zhao TT; Shin KS; Kim KS; Park HJ; Kim HJ; Lee KE; Lee MK
    Neuroscience; 2016 Dec; 339():644-654. PubMed ID: 27789382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic changes detected by proton magnetic resonance spectroscopy in vivo and in vitro in a murin model of Parkinson's disease, the MPTP-intoxicated mouse.
    Chassain C; Bielicki G; Durand E; Lolignier S; Essafi F; Traoré A; Durif F
    J Neurochem; 2008 May; 105(3):874-82. PubMed ID: 18088356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.